ABSTRACT
Rationale As the SARS-CoV-2 pandemic progressed, hospital mortality among patients admitted with COVID-19 decreased; however, its mechanism remains unclear.
Objective To determine underlying factors that might explain the declining observed mortality of hospitalized patients with COVID-19.
Methods This observational study used a prospective COVID-19 clinical database compiled by a 15-hospital health system. Participants were persons testing positive for SARS-CoV-2 (n=185,636), among whom 26,872 were hospitalized for COVID-19 from 3/1/2020 to 6/1/2022.
Measurements Endpoints were hospital and 60-day mortality assessed by randomForests-for-survival machine learning using patient demographics, medical history, symptoms, and admission laboratory test results.
Main Results Mortality of patients hospitalized with COVID-19 fell from 11% in 3/2020 to 3.7% in 3/2022; 60-day mortality was 17% in 5/2020 and 4.7% in 5/2022. Advanced age was the most important predictor of mortality, followed by admission laboratory test results. Risk-adjusted 60-day mortality was 15% had all patients been admitted in 3/2020, minimally unchanged at 12% had they been admitted in 5/2022. Dissociation between observed and predicted mortality was largely explained by change in admission patient profile, particularly admission laboratory test results. Transition to intensive care occurred rapidly for those predicted to do poorly.
Conclusion Mortality from COVID-19 requiring hospitalization has declined as the pandemic has evolved, but surprisingly, persists for 60 days following admission. Demographics, medical history, and at-admission laboratory results continue to accurately predict mortality despite reduction of observed mortality and in spite of therapeutic advances. Importantly, rapid escalation of care can be predicted at admission using standardly obtained information. There has been a subtle but perceptible change in the at-risk population that explains these findings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Cleveland Clinic Health System and Heart, Vascular & Thoracic Institute, Department of Thoracic and Cardiovascular Surgery.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Cleveland Clinic Institutional Review Board (IRB) approved data collection, with informed consent waived (IRB Record 136 under IRB 20-283, 4/27/2020).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding:Cleveland Clinic Health System and Heart, Vascular & Thoracic Institute, Department of Thoracic and Cardiovascular Surgery
Conflict of Interest: None
Ethics: Cleveland Clinic Institutional Review Board approved data collection, with informed consent waived (IRB Record 136 under IRB 20-283, 4/27/2020).
Data Availability
Data used for this study include human research participant data that are sensitive and cannot be publicly shared due to legal and ethical restrictions by the Cleveland Clinic regulatory bodies, including the Institutional Review Board and legal counsel. In particular, variables such as date of testing or dates of hospitalization are HIPAA-protected health information and legally cannot be publicly shared. We will make our data sets available on request, under appropriate data use agreements with the specific parties interested in academic collaboration. Requests for data access can be made to Dr. Sudish C. Murthy.
